Investigating a two-drug combo for advanced lung cancer with specific gene changes
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This trial tests combining two targeted therapies (an EGFR inhibitor and a HER2-targeted drug) for advanced lung cancer that has both an EGFR mutation and a HER2 change. The goal is to see if this combination works better than current treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 75 years old.
- You must be able to perform daily activities with minimal help (ECOG performance status 0 or 1).
- Your lung cancer must be advanced or spread and not removable by surgery.
- You must have an EGFR mutation (either exon 19 deletion or L858R) and a change in the HER2 gene or protein (such as a mutation, amplification, or expression).
- You must not have had prior cancer treatment for advanced disease (except a brief EGFR inhibitor pill within 2 weeks).
- You must not have a history of lung scarring (interstitial lung disease), certain heart conditions, or uncontrolled infections.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests combining two types of cancer drugs—a targeted pill that attacks a specific mutation in your lung cancer cells, followed by an immunotherapy injection when your tumor stops shrinking. The goal is to see if this combination works better than standard treatment alone.
This trial tests a combination of two study drugs for a type of lung cancer that has a specific genetic change (HER2). Doctors want to see if this combination can help treat the cancer when it is advanced.
This trial is testing a new experimental drug (called TQB2928) combined with a standard targeted therapy pill for people with advanced non-small cell lung cancer that has an EGFR mutation. The goal is to see if this combination can help when standard EGFR inhibitors are no longer effective.
This Phase 2 trial tests a combination treatment to control advanced or metastatic non-small cell lung cancer (NSCLC). It is mainly for people whose tumor has specific gene features (EGFR and ALK testing results) and who are able to provide tumor tissue for biomarker testing.
This trial tests a new combination of drugs (trastuzumab deruxtecan, pembrolizumab, and chemotherapy) as a first treatment for people with advanced non-small cell lung cancer that has high levels of the HER2 protein. The goal is to see if this combination works better than current options.
This trial tests a combination of two targeted drugs (almonertinib and anlotinib) as first treatment for advanced non-small cell lung cancer that has specific gene changes (EGFR and TP53 mutations). The goal is to see if the pair works better than standard care.
Hear when a new Lung Cancer (NSCLC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.